Transform healthcare from reactive treatment to proactive preservation of healthspan.
Who we are
The purpose, story, and organization behind Cytognosis.
Cytognosis exists so that no one has to wait years for answers science already has the tools to reveal. This page gathers our purpose, the story behind the science, how we’re organized and funded, our roadmap, and how lived experience and clinical judgment shape the work.
Our Purpose
Why Cytognosis exists.
Before diagnosis. Before symptoms. There’s Cytognosis.
One vision. One mission. One value that keeps both honest.
Detect and preempt the earliest disease signatures, years before clinical onset.
Make precision health a human right, not a privilege of wealth or geography.
Our Story
The story behind the science.
Cytognosis began with a question medicine struggled to answer: what connects conditions that look unrelated, when every specialist sees only one fragment?
Fragmented snapshots→ A coherent map
Loading the founder’s story…
The arc
From personal motivation to founding Cytognosis.
-
01 · Personal motivation
37 years, ten specialists, one hidden mutation.
A research scientist living with unexplained symptoms, misdiagnosed across ten specialties, until his own training named the true cause: a single ultra-rare mutation.
-
02 · Academia
Purdue. MIT. The Broad Institute.
Twenty years of computational biology: multi-cohort atlases of schizophrenia and bipolar disorder, and open-source tools researchers still use, including ACTIONet, TAME, and Kavosh.
-
03 · Industry
insitro. GenBio AI.
Machine learning applied to biology at industry scale, the same conviction that later built Yar’s first working MVP solo, because the tool did not yet exist.
-
04 · Founding Cytognosis
A 501(c)(3), built to belong to everyone.
Incorporated in Delaware, October 2025. Twenty years of computational biology and one personal journey became the founding purpose: open tools, so no one else waits decades for an answer.
Founded so no one else has to wait decades for an answer that was knowable all along.
Our Foundation
A nonprofit built to last.
Cytognosis pairs a mission-locked nonprofit with independent, for-profit execution arms, so open research and commercial scale reinforce each other instead of trading off.
501(c)(3) Nonprofit
Cytognosis Foundation
- Owns the platform’s core intellectual property
- Holds a permanent license for open, mission-aligned research
- Governance majority over any commercial arm
Licenses technology; governance & fair-market safeguards
Public Benefit Corporation
Independent, for-profit arms
- Independently incorporated, outside the Foundation
- Raise their own commercial capital
- Carry a product through regulatory approval and scale
e.g. a company built around Yar, our first consumer companion.
A nonprofit alone tends to hand off its open infrastructure just as the hardest clinical work begins; commercial pressure alone tends to erode access commitments the moment they cost money.
Connecting the two through licensing and governance, rather than a single balance sheet, protects both the mission and the momentum.
This is our governance approach, and we are developing it with legal counsel as the organization grows.
Board of Directors
SM
Shahin Mohammadi
Board Chair & CEO
Founder of Cytognosis; twenty years of computational biology across MIT, the Broad Institute, insitro, and GenBio AI.
AG
Ananth Grama
Board Co-chair
Directs the Institute for Physical AI at Purdue University; Samuel D. Conte Professor of Computer Science.
MM
Madhvi Menon
Board Scientific Advisor
Immunologist and Group Leader at the University of Manchester, studying tissue-infiltrating B cells in chronic disease.
Advisory bodies
We are building complementary advisory bodies to keep lived experience and clinical judgment close to the work. Both are still forming: we are in active conversations with patient-advocacy, clinical, and community organizations to help seat founding members over the coming months.
Lived-Experience Advisory
Brings people with direct experience of the conditions we study into how we decide what to build, and how to build it responsibly.
Patient and Community Advisory
A liaison for clinical-practitioner input, helping make sure what we build actually reaches, and benefits, the people it is meant for.
Cytognosis is not a diagnostic or treatment service. Nothing here replaces the judgment of a qualified clinician. If your organization works in patient advocacy, clinical care, or community health and wants to help shape this work, we would like to hear from you.
Open by design
The same commitment to openness that shapes our technology shapes how we’re built.
Open science
Cytognosis is a nonprofit. Every map, sensor, and model we build ships as open, public infrastructure, not a proprietary asset.
FAIR data
Every dataset, model output, and validation result carries durable identifiers, provenance, and machine-readable structure from the start.
Belongs to everyone
Cytognosis exists so no one else waits decades for answers. What we learn belongs to humanity, not shareholders.
Our Roadmap
Where the work goes from here.
A phased build, from research infrastructure to equitable global access, roughly five years per phase. Every phase publishes its methods and results in the open, as a nonprofit public good.
-
Phase 1Active
Research and development
Cytoverse and Cytoscan research and development, open-source tooling, and multimodal data, starting with neuropsychiatry.
-
Phase 2
Clinical and commercialization
Academic and clinical partners validate our findings on a mission-locked path to reach the people who need them.
-
Phase 3
Globalization and equitable access
Regional partners broaden access to our research and tools, so geography and income don’t decide who benefits first.